Paul Bigliardi is an Atopic Dermatitis / Eczema physician affiliated with University of Minnesota. OpenAlex indexes 130 publications with 3,916 citations (h-index 32); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Paul Bigliardi, PROF, is affiliated with University of Minnesota. The public record shows 130 publications with 3,916 citations (h-index 32), centered on Atopic Dermatitis / Eczema. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 4 companies.
- Most recent indexed publication: 2026 · Dermatitis
- Top research focus: Atopic Dermatitis / Eczema
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone
Sponsor: University of Minnesota
Industry payments
Updated 27 Aug 2026
4 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20258 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- ACADIA Pharmaceuticals IncProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
37.5%Corticosteroid20.7%Mometasone Furoate74%Budesonide-Formoterol Fumarate12%Symbicort8%Dulera6%Part D<11 patientsHistamine-1 Receptor Antagonist6.7%Azelastine Hcl61%Levocetirizine Dihydrochloride39%Part D<11 patientsDermatology
21.4%Interleukin-4 Receptor alpha Antagonist11%Dupixent Syringe56%Dupixent Pen44%Part D<11 patientsInterleukin-13 Antagonist5.8%Adbry100%Part D<11 patientsAnti-infectives
19.5%Penicillin-class Antibacterial16.2%Penicillin g potassium80%Ampicillin sodium20%Part B, office-administered≥28 patientsAzole Antifungal1.9%Ketoconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Progressive expression of PPARGC1α is associated with hair miniaturization in androgenetic alopecia.
Scientific reports
Article2019
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/paul-bigliardi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
experts.umn.edu/en/persons/a8f8cb42-61c4-4883-8bd4-42442b716b66
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →experts.umn.edu ↗ - LinkedIn
linkedin.com/in/paul-bigliardi-6a499175
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/umnderm/posts/congratulations-to-dr-paul-bigliardi-and-his-team-on-the-opening-of-the-new-alle/2440388502716727
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
mhealthfairview.org/blog/Spotlight-Paul-Bigliardi-Diagnosis-Treatment-Allergic-Skin-Reactions
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mhealthfairview.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota